Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$61.74

-0.61 (-0.98%)

13:01
10/07/16
10/07
13:01
10/07/16
13:01

Anthem policy does not mean insurer not covering Sarepta drug, says Baird

Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.

  • 06

    Nov

SRPT Sarepta
$61.74

-0.61 (-0.98%)

09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.

TODAY'S FREE FLY STORIES

VMI

Valmont

$169.70

-1.4 (-0.82%)

07:24
01/23/18
01/23
07:24
01/23/18
07:24
Downgrade
Valmont rating change  »

Valmont downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$45.20

-3.65 (-7.47%)

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Upgrade
Lumentum rating change  »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

MAC

Macerich

$66.00

2.25 (3.53%)

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Periodicals
Ontario Teachers' in talks with investors on Macerich bid, Bloomberg reports »

Ontario Teachers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

07:22
01/23/18
01/23
07:22
01/23/18
07:22
Conference/Events
Washington Journal holds discussion on resolving government shutdown »

The Washington…

NFLX

Netflix

$227.58

7.12 (3.23%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HSGX

Histogenics

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics 2.34M share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GAIA

Gaia

$11.90

-0.05 (-0.42%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Conference/Events
Gaia management to meet with B. Riley »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

07:20
01/23/18
01/23
07:20
01/23/18
07:20
General news
Treasury Market Outlook: global yields tracked lower overnight »

Treasury Market Outlook:…

07:18
01/23/18
01/23
07:18
01/23/18
07:18
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

STT

State Street

$108.99

1.38 (1.28%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Hot Stocks
State Street sees Beacon savings realized 18 months ahead of plan by mid-2019 »

In slides ahead of its Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

W

Wayfair

$90.64

2.8 (3.19%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

07:16
01/23/18
01/23
07:16
01/23/18
07:16
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

VYGR

Voyager Therapeutics

$20.23

1.56 (8.36%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Hot Stocks
Voyager Therapeutics announces FDA clearance of VY-AADC IND application »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$37.00

1 (2.78%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Upgrade
Triumph Bancorp rating change  »

Triumph Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Conference/Events
Boston University to release survey »

Boston University…

CAT

Caterpillar

$170.89

0.48 (0.28%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Upgrade
Caterpillar rating change  »

Caterpillar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

GPRO

GoPro

$6.30

0.01 (0.16%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Downgrade
GoPro rating change  »

GoPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:11
01/23/18
01/23
07:11
01/23/18
07:11
Periodicals
Verizon mulls sports gambling as legalization nears, Bloomberg reports »

Verizon is mulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

, JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Recommendations
Sorrento Therapeutics, Juno Therapeutics, Celgene analyst commentary  »

Juno acquisition bodes…

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 16

    Feb

  • 28

    Feb

  • 25

    Mar

SPX

S&P 500

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

, ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Conference/Events
U.S. Capital Advisors to hold a conference »

Midstream Corporate…

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 26

    Feb

ACBFF

Aurora Cannabis

$11.65

0.8799 (8.17%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Hot Stocks
Aurora Cannabis, CanniMed extending standstill agreement »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.71

0.06 (0.25%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon up marginally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.